Canaccord Genuity Group Forecasts Strong Price Appreciation for Niagen Bioscience (NASDAQ:NAGE) Stock

Niagen Bioscience (NASDAQ:NAGE) had its target price upped by Canaccord Genuity Group from $13.00 to $16.00 in a research note released on Tuesday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

NAGE has been the topic of several other reports. Wall Street Zen downgraded Niagen Bioscience from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 6th. Roth Capital lifted their target price on Niagen Bioscience from $10.00 to $23.00 and gave the company a “buy” rating in a research note on Friday, June 6th.

Niagen Bioscience Stock Up 0.7%

Shares of NAGE stock opened at $13.52 on Tuesday. The company has a 50 day moving average of $8.83. Niagen Bioscience has a twelve month low of $2.31 and a twelve month high of $13.84. The stock has a market cap of $1.06 billion, a P/E ratio of 79.53 and a beta of 2.08.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.